Jaguar Health files 12b-25 for late 10-Q (Mar 31, 2026)

Jaguar Health, Inc. notified the SEC it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 due to delays in obtaining and compiling required information, including material subsequent-event transactions.

Rhea-AI Filing Summary

Jaguar Health, Inc. notified the SEC it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 due to delays in obtaining and compiling required information, including material subsequent-event transactions. The company states it will file the Form 10-Q no later than the fifth calendar day following the prescribed due date.

The notification indicates all other periodic reports for the prior 12 months have been filed and that the company does not anticipate a significant change in results of operations compared with the prior-year period. The form is signed by CFO Carol Lizak.

Insights

Corporate Governance Expert

Late 10-Q filing flagged due to delays compiling subsequent-event information.

The filing states the Form 10-Q for the quarter ended March 31, 2026 could not be completed because the company was still obtaining and compiling material subsequent-event transactions. The company invoked Rule 12b-25 and committed to filing within the fifth calendar day after the prescribed due date.

All other periodic reports for the prior 12 months were filed and the company indicated it does not expect a significant change in reported results versus the comparable prior-year quarter. Subsequent filings will disclose the specific transactions and their effects.

Key Figures

Quarter end: March 31, 2026 Filing extension deadline: fifth calendar day following the prescribed due date Contact phone: 415-371-8300

3 metrics

Quarter end March 31, 2026 Form 10-Q period end

Filing extension deadline fifth calendar day following the prescribed due date Rule 12b-25 commitment

Contact phone 415-371-8300 Registrant contact listed on form

Key Terms

Rule 12b-25, Form 10-Q, material subsequent event transactions

3 terms

Rule 12b-25 regulatory

"could not complete the filing of its Annual Report on Form 10-Q...in accordance with Rule 12b-25"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Form 10-Q regulatory

"could not complete the filing of its Annual Report on Form 10-Q for the quarter ended March 31, 2026"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

material subsequent event transactions financial

"delay in obtaining and compiling information required to be included in the Form 10-Q including significant and material subsequent event transactions"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Jaguar Health (JAGX) file a Form 12b-25 for the quarter ended March 31, 2026?

The company says it delayed filing because it was still obtaining and compiling material subsequent-event transactions. The delay is described as requiring unreasonable effort or expense to eliminate, per Rule 12b-25.

When will Jaguar Health file the late Form 10-Q?

Jaguar Health committed to file the Form 10-Q no later than the fifth calendar day following the prescribed due date. The company used Rule 12b-25 to state this extended filing timeline.

Does the 12b-25 notice say Jaguar Health expects materially different results for the quarter?

The notice explicitly states the company does not anticipate a significant change in results of operations from the comparable prior-year period for the quarter ended March 31, 2026.

Have Jaguar Health's other required periodic reports been filed on time?

Yes. The Form 12b-25 indicates all other periodic reports required under Section 13 or 15(d) during the preceding 12 months have been filed, per the box checked on the form.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 03:06 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

SEC FILE NUMBER 001-36714

CUSIP NUMBER 47010C 862

NOTIFICATION OF LATE FILING

(Check One)		☐ Form 10-K ☐ Form 20-F ☐ Form 11-K  Form 10-Q
		☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR
		For Period Ended: March 31, 2026
		☐  Transition Report on Form 10-K
		☐  Transition Report on Form 20-F
		☐  Transition Report on Form 11-K
		☐  Transition Report on Form 10-Q
		☐  Transition Report on Form N-SAR
		For the Transition Period Ended:

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

Jaguar Health, Inc.

(Full Name of Registrant)

200 Pine Street, Suite 400

San Francisco, CA 94104

(Address of Principal Executive Office (Street and Number))

(City, State and Zip Code)

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

		(a)		The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
		(b)		The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
		(c)		The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Jaguar Health, Inc. (the “Registrant”) could not complete the filing of its Annual Report on Form 10-Q for the quarter ended March 31, 2026 (the “Form 10-Q”) due to a delay in obtaining and compiling information required to be included in the Form 10-Q including significant and material subsequent event transactions, which delay could not be eliminated by the Registrant without unreasonable effort and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the Registrant will file the Form 10-Q no later than the fifth calendar day following the prescribed due date.

(Attach Extra Sheets if Needed)

PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Carol Lizak		415		371-8300
(Name)		(Area Code)		(Telephone Number)

(2)	Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). X Yes ☐  No
(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐  Yes X No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Jaguar Health, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date May 18, 2026 By /s/ Carol Lizak_______________

Carol Lizak

Chief Financial Officer

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).